Compare TLF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLF | NXTC |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.5M | 17.3M |
| IPO Year | 2006 | 2019 |
| Metric | TLF | NXTC |
|---|---|---|
| Price | $2.64 | $6.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 24.6K | ★ 363.5K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 32.05% | N/A |
| EPS Growth | ★ 1122.22 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $76,324,000.00 | $22,378,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $32.38 | ★ N/A |
| Revenue Growth | ★ 2.60 | N/A |
| 52 Week Low | $2.20 | $1.55 |
| 52 Week High | $3.36 | $15.74 |
| Indicator | TLF | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 69.55 | 52.93 |
| Support Level | $2.27 | $3.98 |
| Resistance Level | $2.75 | $10.66 |
| Average True Range (ATR) | 0.09 | 0.97 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 66.27 | 49.06 |
Tandy Leather Factory Inc is a specialty retailers of leather and leathercraft-related items. Its primary line of business is the sale of leather, leather crafts, and related supplies. Its broad line of leather and related products includes leather, leatherworking tools, leather dyes and finishes, and do-it-yourself kits. Its products include Leather, tools, Hardware, Supplies, Kits, Books and Patterns, and Gift cards. The company sells its products primarily through company-owned stores and through orders generated from its global websites, and through direct account representatives in its commercial division. Geographically the company operates within the United States, and Canada. it generates the highest revenue from the United States.
NextCure Inc is a clinical-stage biopharmaceutical company that is focused on advancing inventive medicines that treat cancer patients that do not respond to, or that have disease progression on, current therapies, through the use of targeted therapies including antibody-drug conjugates. The company's product candidates include NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.